B Braun OEM Division - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

B Braun OEM Division


B. Braun OEM Division

Customized Kits – from concept to customization.

As one of the leading companies in the healthcare market, B. Braun is your professional and reliable outsourcing partner for pharmaceutical contract manufacturing and customized medical devices. Our product line has everything for safe and exact infusion therapy.

Based on our extensive product portfolio, long lasting experiences and our complete project management capabilities we are your ideal partner to provide you with standard products or products with modified characteristics assembled in customized kits. Based on your drug we can offer you all disposable items which are required for a certain procedure. You can use your possibility to combine different products or to pair one of our products with one of yours. Your possibilities are nearly endless. We also cover registration issues on the basis of your indications (e.g. labeling, instructions for use, documents, registration).

Visit our booth no. 42F29 at the ICSE in Frankfurt and learn more about how we design, combine and produce customized kits for dozens of applications. We accompany you from your first idea to your individual kit.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here